Sep. 5 at 12:37 PM
$GH ““This approval represents a landmark shift in how we define disease progression and reinforces the transformative role of liquid biopsy in guiding therapy decisions earlier at a critical moment in a breast cancer patient’s treatment journey,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “The SERENA-6 paradigm opens a new frontier in how cancer is managed, with potential application across different diseases and therapies.”
Approximately 37,000 women in the U.S. living with advanced HR-positive breast cancer being treated with an aromatase inhibitor could potentially benefit from this new therapeutic approach leading to better progression-free survival and outcomes.”
